Institution
Orbimed Advisors LLC
13F for June 30, 2026, filed August 14, 2026 · SEC CIK 1055951 · Holdings history from September 30, 2000
- Reported value
- $5.4bn 92% in companies we cover
- Positions we cover
- 112 Largest EWTX 11.7%
- Copy, a year
- +9.9% S&P 500 +11.7%
- Copy Sharpe ratio
- 0.47 S&P 500 0.62
Historical holdings
| Issuer | Class / type | Reported value | Quantity |
|---|---|---|---|
| ABIVAX SA00370M103 · ABVX | SPONSORED ADSCall | $26.7m | 200,000 |
| ABIVAX SA00370M103 · ABVX | SPONSORED ADS | $72.8m | 546,522 |
| ACADIA PHARMACEUTICALS INC004225108 · ACAD | COM | $3.5m | 137,000 |
| ACLARIS THERAPEUTICS INC00461U105 · ACRS | COM | $2.2m | 421,500 |
| ADICET BIO INC007002207 · ACET | COM NEW | $7.3m | 844,787 |
| AGOMAB THERAPEUTICS NV00860C102 · AGMB | SPONSORED ADS | $2.5m | 192,740 |
| ALNYLAM PHARMACEUTICALS INC02043Q107 · ALNY | COM | $5.1m | 17,000 |
| ALTO NEUROSCIENCE INC02157Q109 · ANRO | COM SHS | $6.8m | 257,852 |
| ALUMIS INC022307102 · ALMS | COM | $15.4m | 548,163 |
| ALX ONCOLOGY HLDGS INC00166B105 · ALXO | COM | $5.9m | 2,866,256 |
| AMYLYX PHARMACEUTICALS INC03237H101 · AMLX | COM | $3.3m | 183,400 |
| ARCUTIS BIOTHERAPEUTICS INC03969K108 · ARQT | COM | $53.5m | 2,042,000 |
| ARGENX SE04016X101 · ARGX | SPONSORED ADR | $86.2m | 92,880 |
| ARRIVENT BIOPHARMA INC04272N102 · AVBP | COM | $105.2m | 3,027,328 |
| ARS PHARMACEUTICALS INC82835W108 · SPRY | COM | $66.4m | 8,288,510 |
| ARTIVION INC228903100 · AORT | COM | $3.9m | 175,000 |
| ASCENDIS PHARMA A/SK08588103 · ASND | ORD SHS | $65.2m | 244,456 |
| ASTRAZENECA PLCG0593M107 · AZN | ORD | $171.1m | 915,700 |
| PRELUDE THERAPEUTICS INC74065P101 · PRLD | COM | $73.2m | 13,724,571 |
| PRELUDE THERAPEUTICS INC000000000 | NON VOTING | $30.3m | 5,680,186 |
| PROTAGONIST THERAPEUTICS INC74366E102 · PTGX | COM | $5.2m | 42,100 |
| PROTAGONIST THERAPEUTICS INC74366E102 · PTGX | COMCall | $18.4m | 150,000 |
| PROTARA THERAPEUTICS INC74365U107 · TARA | COM STK | $8.5m | 2,220,000 |
| PTC THERAPEUTICS INC69366J200 · PTCT | COM | $4.0m | 49,100 |
| Q32 BIO INC746964105 · QTTB | COM | $52.6m | 4,127,987 |
| RAPPORT THERAPEUTICS INC75383L102 · RAPP | COM | $3.2m | 76,616 |
| RELMADA THERAPEUTICS INC75955J402 · RLMD | COM | $25.1m | 3,631,195 |
| REVOLUTION MEDICINES INC76155X100 · RVMD | COMCall | $9.4m | 50,000 |
| REVOLUTION MEDICINES INC76155XAA8 | NOTE 0.500% 5/0 | $4.4m | 3,500,000 |
| REVOLUTION MEDICINES INC76155X100 · RVMD | COM | $13.2m | 70,500 |
| RHYTHM PHARMACEUTICALS INC76243J105 · RYTM | COM | $35.9m | 322,900 |
| SAVARA INC805111101 · SVRA | COM | $24.4m | 3,959,900 |
| SELLAS LIFE SCIENCES GROUP I81642T209 · SLS | COM NEWPut | $1.4m | 92,500 |
| SHATTUCK LABS INC82024L103 · STTK | COM | $43.8m | 6,306,127 |
| SINOVAC BIOTECH LTDP8696W104 | SHS | $184.5m | 2,718,735 |
| SIONNA THERAPEUTICS INC829401108 · SION | COM | $112.4m | 2,555,877 |
| SPDR SERIES TRUST78464A870 | ST STR SP BIOTPut | $47.5m | 300,000 |
| SPRUCE BIOSCIENCES INC85209E208 · SPRB | COM NEW | $10.8m | 200,000 |
| SPYRE THERAPEUTICS INC00773J202 · SYRE | COM NEW | $16.5m | 186,145 |
| STRUCTURE THERAPEUTICS INC86366E106 · GPCR | SPONSORED ADS | $118.6m | 2,209,400 |
| STRYKER CORPORATION863667101 · SYK | COM | $50.1m | 159,100 |
| SUTRO BIOPHARMA INC869367201 · STRO | COM SHS | $24.7m | 743,944 |
| SYNDAX PHARMACEUTICALS INC87164F105 · SNDX | COM | $33.7m | 1,542,000 |
| TARSUS PHARMACEUTICALS INC87650L103 · TARS | COM | $2.2m | 35,581 |
| TAYSHA GENE THERAPIES INC877619106 · TSHA | COM SHS | $13.6m | 2,000,000 |
| TECTONIC THERAPEUTIC INC878972108 · TECX | COM | $7.8m | 226,600 |
| THERMO FISHER SCIENTIFIC INC883556102 · TMO | COM | $45.5m | 90,700 |
| TRAVERE THERAPEUTICS INC89422G107 · TVTX | COM | $14.4m | 253,000 |
| TRAVERE THERAPEUTICS INC89422GAB3 | NOTE 0.500% 5/1 | $5.9m | 5,000,000 |
| TRAWS PHARMA INC68232V884 · TRAW | COM NEW | $1.0m | 1,203,260 |
| TREVI THERAPEUTICS INC89532M101 · TRVI | COM | $26.7m | 1,430,293 |
| TYRA BIOSCIENCES INC90240B106 · TYRA | COM | $3.3m | 102,000 |
| UNIQURE NVN90064101 · QURE | SHS | $83.3m | 1,807,486 |
| UNITEDHEALTH GROUP INC91324P102 · UNH | COM | $67.0m | 161,100 |
| UNITEDHEALTH GROUP INC91324P102 · UNH | COMCall | $4.2m | 10,000 |
| UPSTREAM BIO INC91678A107 · UPB | COM | $39.4m | 5,693,589 |
| UROGEN PHARMA LTDM96088105 · URGN | COM | $24.9m | 676,187 |
| VERA THERAPEUTICS INC92337R101 · VERA | CL A | $15.9m | 369,596 |
| VIRIDIAN THERAPEUTICS INC92790CAB0 | NOTE 1.750% 5/1 | $1.1m | 1,000,000 |
| WATERS CORP941848103 · WAT | COM | $15.1m | 40,300 |
| WEST PHARMACEUTICAL SVSC INC955306105 · WST | COM | $25.3m | 70,600 |
| WHITEHAWK THERAPEUTICS INC00032Q104 · WHWK | COM | $18.0m | 3,934,296 |
| XENON PHARMACEUTICALS INC98420N105 · XENE | COM | $53.9m | 892,471 |
| XILIO THERAPEUTICS INC98422T209 · XLO | COM | $5.7m | 592,300 |
| ZENTALIS PHARMACEUTICALS INC98943L107 · ZNTL | COM | $6.7m | 1,390,576 |
| ATAIBECKLEY INC04650F101 | COM SHS | $4.2m | 797,500 |
| AURA BIOSCIENCES INC05153U107 · AURA | COM | $23.7m | 3,333,333 |
| AXSOME THERAPEUTICS INC.05464T104 · AXSM | COM | $28.8m | 117,578 |
| BELITE BIO INC07782B104 · BLTE | SPONSORED ADS | $2.0m | 13,300 |
| BICARA THERAPEUTICS INC055477103 · BCAX | COM | $5.7m | 191,100 |
| BIOAGE LABS INC09077V100 · BIOA | COM | $18.4m | 752,153 |
| BIOCRYST PHARMACEUTICALS INC09058V103 · BCRX | COM | $18.5m | 1,852,000 |
| BIOGEN INC09062X103 · BIIB | COM | $13.3m | 61,600 |
| BOSTON SCIENTIFIC CORP101137107 · BSX | COM | $63.3m | 1,483,200 |
| BRIGHT MINDS BIOSCIENCES INC10919W405 · DRUG | COM NEW | $6.5m | 93,000 |
| BRISTOL-MYERS SQUIBB CO110122108 · BMY | COM | $53.3m | 925,000 |
| CARIS LIFE SCIENCES INC142152107 · CAI | COM | $50.0m | 2,806,811 |
| CG ONCOLOGY INC156944100 · CGON | COM | $69.1m | 972,800 |
| COGENT BIOSCIENCES INC19240QAA0 | NOTE 1.625%11/1 | $1.2m | 1,000,000 |
| COGENT BIOSCIENCES INC19240Q201 · COGT | COM | $65.1m | 1,681,300 |
| COMPASS THERAPEUTICS INC20454B104 · CMPX | COM | $33.3m | 15,219,994 |
| CORBUS PHARMACEUTICALS HLDGS21833P301 · CRBP | COM NEW | $16.3m | 1,737,287 |
| CORVUS PHARMACEUTICALS INC221015100 · CRVS | COM | $107.0m | 7,165,006 |
| CRINETICS PHARMACEUTICALS IN22663K107 | COM | $37.4m | 999,000 |
| CYBIN INC23256X407 · HELP | COM NEW | $21.6m | 3,271,400 |
| CYTOKINETICS INC23282W605 · CYTK | COM NEW | $2.2m | 25,800 |
| DEFINIUM THERAPEUTICS INC24477V105 · DFTX | COM SHS | $17.2m | 365,400 |
| DIANTHUS THERAPEUTICS INC252828108 · DNTH | COM | $11.2m | 115,000 |
| DISC MEDICINE INC254604101 · IRON | COM | $26.2m | 357,535 |
| DYNE THERAPEUTICS INC26818M108 · DYN | COM | $71.9m | 3,235,684 |
| EDGEWISE THERAPEUTICS INC28036F105 · EWTX | COM | $630.5m | 15,518,492 |
| EDWARDS LIFESCIENCES CORP28176E108 · EW | COM | $75.5m | 834,900 |
| ELEVANCE HEALTH INC FORMERLY036752103 · ELV | COMCall | $3.9m | 10,000 |
| ELEVANCE HEALTH INC FORMERLY036752103 · ELV | COM | $44.4m | 114,700 |
| ELI LILLY & CO532457108 · LLY | COM | $309.3m | 257,900 |
| ENLIVEN THERAPEUTICS INC29337E102 · ELVN | COM | $343.9m | 6,776,632 |
| ERASCA INC29479A108 · ERAS | COM | $9.1m | 495,900 |
| EUPRAXIA PHARMACEUTICALS INC29842P105 · EPRX | COM | $1.8m | 269,000 |
| EVOMMUNE INC30054Y107 · EVMN | COM SHS | $2.1m | 161,000 |
| EYEPOINT INC30233G209 · EYPT | COM NEW | $15.3m | 1,069,147 |
How copying its 13F would have done
Reported value by quarter
View chart data
| Period | Reported value |
|---|---|
| 2008-03-31 | $3.1B |
| 2008-06-30 | $3.4B |
| 2008-09-30 | $3.5B |
| 2008-12-31 | $2.7B |
| 2009-03-31 | $2.4B |
| 2009-06-30 | $2.6B |
| 2009-09-30 | $2.8B |
| 2009-12-31 | $2.6B |
| 2010-03-31 | $3.4B |
| 2010-06-30 | $2.7B |
| 2010-09-30 | $2.9B |
| 2010-12-31 | $2.8B |
| 2011-03-31 | $3B |
| 2011-06-30 | $3.2B |
| 2011-09-30 | $2.7B |
| 2011-12-31 | $3B |
| 2012-03-31 | $3.4B |
| 2012-06-30 | $3.6B |
| 2012-09-30 | $3.5B |
| 2012-12-31 | $3.3B |
| 2013-03-31 | $4.3B |
| 2013-06-30 | $4.7B |
| 2013-09-30 | $5.6B |
| 2013-12-31 | $6.8B |
| 2014-03-31 | $8.1B |
| 2014-06-30 | $8.5B |
| 2014-09-30 | $9.6B |
| 2014-12-31 | $10.5B |
| 2015-03-31 | $11.7B |
| 2015-06-30 | $13.6B |
| 2015-09-30 | $9.9B |
| 2015-12-31 | $11B |
| 2016-03-31 | $9.5B |
| 2016-06-30 | $9.6B |
| 2016-09-30 | $8.8B |
| 2016-12-31 | $7.8B |
| 2017-03-31 | $8.8B |
| 2017-06-30 | $9.5B |
| 2017-09-30 | $10.5B |
| 2017-12-31 | $7.9B |
| 2018-03-31 | $8.1B |
| 2018-06-30 | $8.4B |
| 2018-09-30 | $8.3B |
| 2018-12-31 | $5.4B |
| 2019-03-31 | $6.5B |
| 2019-06-30 | $6.5B |
| 2019-09-30 | $5.3B |
| 2019-12-31 | $7B |
| 2020-03-31 | $6B |
| 2020-06-30 | $7.1B |
| 2020-09-30 | $8B |
| 2020-12-31 | $11.4B |
| 2021-03-31 | $10.7B |
| 2021-06-30 | $9.9B |
| 2021-09-30 | $9.1B |
| 2021-12-31 | $7.8B |
| 2022-03-31 | $6.2B |
| 2022-06-30 | $5.5B |
| 2022-09-30 | $5.4B |
| 2022-12-31 | $5.2B |
| 2023-03-31 | $5.1B |
| 2023-06-30 | $5.5B |
| 2023-09-30 | $4.7B |
| 2023-12-31 | $5B |
| 2024-03-31 | $5.5B |
| 2024-06-30 | $5.1B |
| 2024-09-30 | $5.5B |
| 2024-12-31 | $4.9B |
| 2025-03-31 | $4.2B |
| 2025-06-30 | $4B |
| 2025-09-30 | $4.3B |
| 2025-12-31 | $4.9B |
| 2026-03-31 | $5B |
| 2026-06-30 | $5.4B |
Latest covered holdings and moves
| Company | Share of portfolio | Value | Shares | Change in shares |
|---|---|---|---|---|
| EWTXEdgewise Therapeutics, Inc. | 11.68% | $630.5m | 15.52M | 0.0% |
| ELVNEnliven Therapeutics, Inc. | 6.37% | $343.9m | 6.78M | −14.9% Reduced |
| LLYLilly (Eli) | 5.73% | $309.3m | 257.9K | +8.9% Added |
| MBXMBX Biosciences, Inc. | 3.51% | $189.3m | 3.43M | −5.7% Reduced |
| AZNAstrazeneca PLC | 3.17% | $171.1m | 915.7K | +36.6% Added |
| GPCRStructure Therapeutics Inc. | 2.20% | $118.6m | 2.21M | +49.7% Added |
| SIONSionna Therapeutics, Inc. | 2.08% | $112.4m | 2.56M | −27.6% Reduced |
| CRVSCorvus Pharmaceuticals, Inc. | 1.98% | $107.0m | 7.17M | 0.0% |
| AVBPArrivent Biopharma, Inc. | 1.95% | $105.2m | 3.03M | 0.0% |
| GHGuardant Health, Inc. | 1.62% | $87.6m | 583.7K | +34.1% Added |
| ARGXArgenx SE | 1.60% | $86.2m | 92.9K | −32.2% Reduced |
| MRKMerck & Co. | 1.58% | $85.2m | 663.4K | 0.0% |
| QUREUniqure N.V. | 1.54% | $83.3m | 1.81M | −15.4% Reduced |
| PRAXPraxis Precision Medicines, Inc. | 1.43% | $77.0m | 230.1K | +33.4% Added |
| EWEdwards Lifesciences | 1.40% | $75.5m | 834.9K | −32.2% Reduced |
| PRLDPrelude Therapeutics Inc | 1.35% | $73.2m | 13.72M | +25.8% Added |
| ABVXAbivax S.a. | 1.35% | $72.8m | 546.5K | +17.4% Added |
| DYNDyne Therapeutics, Inc. | 1.33% | $71.9m | 3.24M | +10.9% Added |
| NTRANatera, Inc. | 1.32% | $71.1m | 262.0K | 0.0% |
| CGONCG Oncology, Inc. | 1.28% | $69.1m | 972.8K | +2.6% Added |
| UNHUnitedHealth Group | 1.24% | $67.0m | 161.1K | New |
| SPRYARS Pharmaceuticals, Inc. | 1.23% | $66.4m | 8.29M | 0.0% |
| ASNDAscendis Pharma A/s | 1.21% | $65.2m | 244.5K | +34.3% Added |
| HUMHumana | 1.21% | $65.2m | 164.1K | New |
| COGTCogent Biosciences, Inc. | 1.21% | $65.1m | 1.68M | +422.0% Added |
| BSXBoston Scientific | 1.17% | $63.3m | 1.48M | −37.7% Reduced |
| ISRGIntuitive Surgical | 1.16% | $62.8m | 157.9K | −24.3% Reduced |
| MLYSMineralys Therapeutics, Inc. | 1.05% | $56.9m | 2.11M | +2.8% Added |
| ODTXOdyssey Therapeutics, Inc. | 1.04% | $56.2m | 3.00M | New |
| XENEXenon Pharmaceuticals Inc. | 1.00% | $53.9m | 892.5K | −15.8% Reduced |
| ARQTArcutis Biotherapeutics, Inc. | 0.99% | $53.5m | 2.04M | New |
| BMYBristol Myers Squibb | 0.99% | $53.3m | 925.0K | 0.0% |
| QTTBQ32 Bio Inc. | 0.97% | $52.6m | 4.13M | +83.2% Added |
| SYKStryker Corporation | 0.93% | $50.1m | 159.1K | −12.8% Reduced |
| CAICaris Life Sciences, Inc. | 0.93% | $50.0m | 2.81M | 0.0% |
| TMOThermo Fisher Scientific | 0.84% | $45.5m | 90.7K | +95.1% Added |
| PVLAPalvella Therapeutics, Inc. | 0.83% | $44.7m | 292.4K | +117.2% Added |
| ELVElevance Health | 0.82% | $44.4m | 114.7K | 0.0% |
| STTKShattuck Labs, Inc. | 0.81% | $43.8m | 6.31M | 0.0% |
| UPBUpstream Bio, Inc. | 0.73% | $39.4m | 5.69M | 0.0% |
| RYTMRhythm Pharmaceuticals, Inc. | 0.66% | $35.9m | 322.9K | +2.8% Added |
| SNDXSyndax Pharmaceuticals Inc | 0.63% | $33.7m | 1.54M | +60.2% Added |
| CMPXCompass Therapeutics, Inc. | 0.62% | $33.3m | 15.22M | 0.0% |
| NKTRNektar Therapeutics | 0.60% | $32.5m | 465.3K | +69.2% Added |
| KRYSKrystal Biotech, Inc. | 0.57% | $30.9m | 83.2K | +20.4% Added |
| AXSMAxsome Therapeutics, Inc. | 0.53% | $28.8m | 117.6K | −45.0% Reduced |
| KNSAKiniksa Pharmaceuticals International, plc | 0.50% | $26.9m | 420.6K | +132.9% Added |
| TRVITrevi Therapeutics, Inc. | 0.49% | $26.7m | 1.43M | −41.7% Reduced |
| IRONDisc Medicine, Inc. | 0.48% | $26.2m | 357.5K | −66.5% Reduced |
| WSTWest Pharmaceutical Services | 0.47% | $25.3m | 70.6K | New |
| RLMDRelmada Therapeutics, Inc. | 0.47% | $25.1m | 3.63M | −23.0% Reduced |
| URGNUrogen Pharma Ltd. | 0.46% | $24.9m | 676.2K | −22.8% Reduced |
| STROSutro Biopharma, Inc. | 0.46% | $24.7m | 743.9K | −7.1% Reduced |
| SVRASavara Inc | 0.45% | $24.4m | 3.96M | +523.6% Added |
| NPCENeuropace Inc | 0.44% | $23.9m | 1.51M | −28.2% Reduced |
| AURAAura Biosciences, Inc. | 0.44% | $23.7m | 3.33M | New |
| ORICOric Pharmaceuticals, Inc. | 0.40% | $21.8m | 2.02M | −25.2% Reduced |
| HELPHelus Pharma Inc. | 0.40% | $21.6m | 3.27M | −14.6% Reduced |
| BCRXBiocryst Pharmaceuticals Inc | 0.34% | $18.5m | 1.85M | +29.9% Added |
| BIOABioage Labs, Inc. | 0.34% | $18.4m | 752.2K | +5.7% Added |
| LXEOLexeo Therapeutics, Inc. | 0.34% | $18.4m | 3.95M | +9.6% Added |
| WHWKWhitehawk Therapeutics, Inc. | 0.33% | $18.0m | 3.93M | −5.6% Reduced |
| DFTXDefinium Therapeutics, Inc. | 0.32% | $17.2m | 365.4K | −54.6% Reduced |
| SYRESpyre Therapeutics, Inc. | 0.31% | $16.5m | 186.1K | New |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | 0.30% | $16.3m | 1.74M | 0.0% |
| VERAVera Therapeutics, Inc. | 0.29% | $15.9m | 369.6K | 0.0% |
| ALMSAlumis Inc. | 0.29% | $15.4m | 548.2K | 0.0% |
| EYPTEyepoint, Inc. | 0.28% | $15.3m | 1.07M | 0.0% |
| WATWaters Corporation | 0.28% | $15.1m | 40.3K | New |
| MNPRMonopar Therapeutics | 0.27% | $14.6m | 157.4K | New |
| TVTXTravere Therapeutics, Inc. | 0.27% | $14.4m | 253.0K | New |
| TSHATaysha Gene Therapies, Inc. | 0.25% | $13.6m | 2.00M | New |
| BIIBBiogen | 0.25% | $13.3m | 61.6K | 0.0% |
| RVMDRevolution Medicines, Inc. | 0.24% | $13.2m | 70.5K | +35.6% Added |
| DNTHDianthus Therapeutics, Inc. | 0.21% | $11.2m | 115.0K | New |
| SPRBSpruce Biosciences, Inc. | 0.20% | $10.8m | 200.0K | New |
| LFSTLifestance Health Group, Inc. | 0.19% | $10.1m | 947.4K | +89.5% Added |
| ERASErasca, Inc. | 0.17% | $9.1m | 495.9K | New |
| TARAProtara Therapeutics, Inc. | 0.16% | $8.5m | 2.22M | New |
| KROSKeros Therapeutics, Inc. | 0.15% | $8.1m | 759.2K | 0.0% |
| JANXJanux Therapeutics, Inc. | 0.15% | $8.1m | 524.7K | −46.7% Reduced |
| TECXTectonic Therapeutic, Inc. | 0.14% | $7.8m | 226.6K | 0.0% |
| ACETAdicet Bio, Inc. | 0.14% | $7.3m | 844.8K | −17.8% Reduced |
| PHVSPharvaris N.V. | 0.13% | $7.1m | 205.4K | 0.0% |
| ANROAlto Neuroscience, Inc. | 0.13% | $6.8m | 257.9K | +53.9% Added |
| ZNTLZentalis Pharmaceuticals, Inc. | 0.13% | $6.7m | 1.39M | New |
| DRUGBright Minds Biosciences Inc. | 0.12% | $6.5m | 93.0K | +132.5% Added |
| ALXOALX Oncology Holdings Inc | 0.11% | $5.9m | 2.87M | 0.0% |
| XLOXilio Therapeutics, Inc. | 0.10% | $5.7m | 592.3K | New |
| BCAXBicara Therapeutics Inc. | 0.10% | $5.7m | 191.1K | −71.4% Reduced |
| IMAImagenebio, Inc. | 0.10% | $5.4m | 909.3K | +140.2% Added |
| PTGXProtagonist Therapeutics, Inc | 0.10% | $5.2m | 42.1K | 0.0% |
| ALNYAlnylam Pharmaceuticals, Inc. | 0.10% | $5.1m | 17.0K | −85.7% Reduced |
| PALIPalisade BIO, Inc. | 0.09% | $4.9m | 2.33M | 0.0% |
| PTCTPTC Therapeutics, Inc. | 0.07% | $4.0m | 49.1K | 0.0% |
| AORTArtivion, Inc. | 0.07% | $3.9m | 175.0K | +15.9% Added |
| NMRANeumora Therapeutics, Inc. | 0.07% | $3.6m | 2.14M | New |
| ACADAcadia Pharmaceuticals Inc | 0.06% | $3.5m | 137.0K | New |
| AMLXAmylyx Pharmaceuticals, Inc. | 0.06% | $3.3m | 183.4K | New |
| TYRATyra Biosciences, Inc. | 0.06% | $3.3m | 102.0K | New |
| RAPPRapport Therapeutics, Inc. | 0.06% | $3.2m | 76.6K | New |
| AGMBAgomab Therapeutics NV | 0.05% | $2.5m | 192.7K | New |
| TARSTarsus Pharmaceuticals, Inc. | 0.04% | $2.2m | 35.6K | New |
| ACRSAclaris Therapeutics, Inc. | 0.04% | $2.2m | 421.5K | New |
| CYTKCytokinetics Inc | 0.04% | $2.2m | 25.8K | New |
| NSPRInspiremd, Inc. | 0.04% | $2.2m | 3.13M | 0.0% |
| OCULOcular Therapeutix, Inc | 0.04% | $2.2m | 220.0K | New |
| EVMNEvommune, Inc. | 0.04% | $2.1m | 161.0K | New |
| BLTEBelite BIO, Inc | 0.04% | $2.0m | 13.3K | New |
| OVIDOvid Therapeutics Inc. | 0.04% | $2.0m | 747.0K | New |
| EPRXEupraxia Pharmaceuticals Inc. | 0.03% | $1.8m | 269.0K | New |
| TRAWTraws Pharma, Inc. | 0.02% | $1.0m | 1.20M | +98.7% Added |
| Company | Bought (value) | Shares |
|---|---|---|
| UNHUnitedHealth Group | $67.0m | 161.1K |
| HUMHumana | $65.2m | 164.1K |
| ODTXOdyssey Therapeutics, Inc. | $56.2m | 3.00M |
| ARQTArcutis Biotherapeutics, Inc. | $53.5m | 2.04M |
| COGTCogent Biosciences, Inc. | $52.6m | 1.36M |
| AZNAstrazeneca PLC | $45.9m | 245.5K |
| GPCRStructure Therapeutics Inc. | $39.4m | 734.0K |
| WSTWest Pharmaceutical Services | $25.3m | 70.6K |
| LLYLilly (Eli) | $25.3m | 21.1K |
| PVLAPalvella Therapeutics, Inc. | $24.1m | 157.8K |
| QTTBQ32 Bio Inc. | $23.9m | 1.88M |
| AURAAura Biosciences, Inc. | $23.7m | 3.33M |
| GHGuardant Health, Inc. | $22.3m | 148.5K |
| TMOThermo Fisher Scientific | $22.2m | 44.2K |
| SVRASavara Inc | $20.5m | 3.32M |
| Company | Sold (value) | Shares |
|---|---|---|
| ELVNEnliven Therapeutics, Inc. | −$60.0m | −1.18M |
| PFEPfizer | −$54.7m | −1.95M |
| IRONDisc Medicine, Inc. | −$51.9m | −710.0K |
| DHRDanaher Corporation | −$50.4m | −265.8K |
| SIONSionna Therapeutics, Inc. | −$42.9m | −974.8K |
| ARGXArgenx SE | −$40.8m | −44.0K |
| BSXBoston Scientific | −$38.4m | −898.9K |
| EWEdwards Lifesciences | −$35.8m | −395.7K |
| ALNYAlnylam Pharmaceuticals, Inc. | −$30.7m | −102.0K |
| AXSMAxsome Therapeutics, Inc. | −$23.6m | −96.3K |
| BTSGBrightspring Health Services, Inc. | −$21.2m | −497.8K |
| DFTXDefinium Therapeutics, Inc. | −$20.6m | −438.6K |
| ISRGIntuitive Surgical | −$20.2m | −50.8K |
| TRVITrevi Therapeutics, Inc. | −$19.1m | −1.02M |
| QUREUniqure N.V. | −$15.1m | −328.7K |
| Company | Value last quarter | Shares |
|---|---|---|
| PFEPfizer | $54.7m | 1.95M |
| DHRDanaher Corporation | $50.4m | 265.8K |
| BTSGBrightspring Health Services, Inc. | $21.2m | 497.8K |
| AMGNAmgen | $14.0m | 39.9K |
| ALHCAlignment Healthcare, Inc. | $13.9m | 791.0K |
| REGNRegeneron Pharmaceuticals | $11.4m | 14.7K |
| CARLCarlsmed, Inc. | $11.3m | 1.25M |
| GILDGilead Sciences | $8.3m | 59.6K |
| HRTXHeron Therapeutics, Inc. | $7.9m | 9.82M |
| AVTXAvalo Therapeutics, Inc. | $7.1m | 475.2K |
| CMPSCompass Pathways plc | $6.4m | 1.15M |
| ADCTADC Therapeutics SA | $4.9m | 1.32M |
| CGEMCullinan Therapeutics, Inc. | $3.5m | 243.0K |
| JBIOJade Biosciences, Inc. | $2.6m | 185.0K |
| CCCCC4 Therapeutics, Inc. | $2.3m | 856.4K |
| RCELAvita Medical, Inc. | $2.0m | 544.9K |
| VTGNVistagen Therapeutics, Inc. | $1.7m | 3.06M |
| Period | Copy, a year | S&P 500 | Sharpe | S&P 500 | Biggest drop | Beta |
|---|---|---|---|---|---|---|
| Whole backtestFebruary 15, 2008 to November 2, 2026 | +9.9% | +11.7% | 0.47 | 0.62 | −52.3% | 0.87 |
| 2010 to 2017January 8, 2010 to December 29, 2017 | +18.2% | +13.5% | 1.08 | 0.98 | −25.4% | 0.89 |
| 2018 onwardsJanuary 5, 2018 to November 2, 2026 | +3.8% | +13.9% | 0.16 | 0.66 | −52.3% | 0.96 |
| Last three yearsNovember 3, 2023 to November 2, 2026 | +16.0% | +21.8% | 0.54 | 1.16 | −34.1% | 1.02 |
| Last yearNovember 7, 2025 to November 2, 2026 | +7.4% | +14.2% | 0.25 | 0.84 | −22.4% | 0.92 |